Genomics Technique Accelerate Detection of Foodborne Bacterial Outbreaks
|
By LabMedica International staff writers Posted on 15 Dec 2016 |

Image: Bacterial colonies of Staphylococcus aureus growing on horse blood agar (Photo courtesy of OMICS International).
Diagnostic testing for foodborne pathogens relies on culture-based techniques that are not rapid enough for real-time disease surveillance and do not give a quantitative picture of pathogen abundance or the response of the natural microbiome.
Metagenomics identifies the microbes present by sequencing the entire DNA present in a sample and comparing the genomic data to a database of known microbes. In addition to identifying the bacteria present in the samples, the methodology can also measure the relative abundance of each microbial species and their virulence potential, among other things.
A collaboration of scientists from the Centers for Disease Control and Prevention (Atlanta, GA USA) and the Georgia Institute of Technology (Atlanta, GA, USA) applied shotgun metagenomics to stool samples collected from two geographically isolated foodborne outbreaks in Alabama and Colorado, where the etiologic agents were identified as distinct strains of Salmonella enterica serovar Heidelberg by culture-dependent methods. The metagenomics data provided specific information about the bacterial phenotype involved and identified a secondary Staphylococcus aureus pathogen present in two of the samples tested. Knowing the specific phenotype can help in pinpointing the origins of an outbreak, while information about the secondary infection may help explain related factors such as the severity of the infection.
The scientists were also able to rule out one species, Escherichia coli (or E. coli), because the variant present was not of a virulent type. Variants of these bacteria are present naturally in the gut microbiome (called "commensal E. coli") while other variants are notorious enteric pathogens. Metagenomics showed the abundant E. coli population in the outbreak samples was probably commensal, and its growth may have been accelerated when conditions became more favorable during the Salmonella infection. In the two cases evaluated, scientists were able to determine that although the symptoms were similar, the outbreaks were caused by different variants of Salmonella and therefore were probably not connected.
Andrew D. Huang, PhD, a microbiologist/ bioinformatician and lead author of the study said, “Currently, the most advanced DNA fingerprinting method, whole genome sequencing, requires first pulling out, or isolating in a pure culture, the bacteria that made a person sick to generate a fingerprint. Metagenomics differs from whole genome sequencing because it could allow us to sequence the entire DNA in a patient's sample. It could allow us to skip the isolation steps and go directly from a stool sample to a highly detailed DNA fingerprint of the bacteria that made you sick. This method saves time and provides more detail that could be helpful for diagnosing a patient and identifying an outbreak.” The study was published on November 23, 2016, in the journal Applied and Environmental Microbiology.
Related Links:
Centers for Disease Control and Prevention
Georgia Institute of Technology
Metagenomics identifies the microbes present by sequencing the entire DNA present in a sample and comparing the genomic data to a database of known microbes. In addition to identifying the bacteria present in the samples, the methodology can also measure the relative abundance of each microbial species and their virulence potential, among other things.
A collaboration of scientists from the Centers for Disease Control and Prevention (Atlanta, GA USA) and the Georgia Institute of Technology (Atlanta, GA, USA) applied shotgun metagenomics to stool samples collected from two geographically isolated foodborne outbreaks in Alabama and Colorado, where the etiologic agents were identified as distinct strains of Salmonella enterica serovar Heidelberg by culture-dependent methods. The metagenomics data provided specific information about the bacterial phenotype involved and identified a secondary Staphylococcus aureus pathogen present in two of the samples tested. Knowing the specific phenotype can help in pinpointing the origins of an outbreak, while information about the secondary infection may help explain related factors such as the severity of the infection.
The scientists were also able to rule out one species, Escherichia coli (or E. coli), because the variant present was not of a virulent type. Variants of these bacteria are present naturally in the gut microbiome (called "commensal E. coli") while other variants are notorious enteric pathogens. Metagenomics showed the abundant E. coli population in the outbreak samples was probably commensal, and its growth may have been accelerated when conditions became more favorable during the Salmonella infection. In the two cases evaluated, scientists were able to determine that although the symptoms were similar, the outbreaks were caused by different variants of Salmonella and therefore were probably not connected.
Andrew D. Huang, PhD, a microbiologist/ bioinformatician and lead author of the study said, “Currently, the most advanced DNA fingerprinting method, whole genome sequencing, requires first pulling out, or isolating in a pure culture, the bacteria that made a person sick to generate a fingerprint. Metagenomics differs from whole genome sequencing because it could allow us to sequence the entire DNA in a patient's sample. It could allow us to skip the isolation steps and go directly from a stool sample to a highly detailed DNA fingerprint of the bacteria that made you sick. This method saves time and provides more detail that could be helpful for diagnosing a patient and identifying an outbreak.” The study was published on November 23, 2016, in the journal Applied and Environmental Microbiology.
Related Links:
Centers for Disease Control and Prevention
Georgia Institute of Technology
Latest Microbiology News
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







